International - September 2015 Archives

ROCHESTER, Minn. – Mayo Clinic researchers have identified a protein marker whose frequency may predict patient response to PD-1 blockade immunotherapy for melanoma. An abstract of their findings was presented today at the American Association for Cancer Research International Cancer Immunotherapy Conference in New York City. “The discovery of biomarkers of sensitivity are vital not only for informing clinical decisions, but also to help identify which patients with melanoma, and possibly other malignancies, who are most likely to benefit from PD-1 blockade," says Roxana Dronca, M.D., a hematologist at Mayo Clinic and lead author of the abstract. “This will allow us to expose fewer patients to inadequate treatments, and their associated toxicities and costs.” https://www.youtube.com/watch?v=ava8Q6n_Y8o Journalists:  Sound bites with Dr. Dronca are available in the downloads.